Overview

A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the clinical efficacy and safety in patients with Acute Bronchitis or Secondary Infection of Chronic Respiratory Diseases receiving a dose of 2 g of azithromycin in the SR formulation.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Azithromycin
Criteria
Inclusion Criteria:

- Patients who were diagnosed as mild or moderate in severity by the classification of
infection of the Japanese Society of Chemotherapy guidelines for the evaluation
methods of new antibacterial drug (established in 1997).

Exclusion Criteria:

- Severe underlying disease; patients in which drug clinical evaluation is difficult
because of confounding diseases.